Novo Nordisk's phase 2 trial of investigational zenagamtide shows significant HbA1C reductions with up to 14.6% weight loss in adults with type 2 diabetes

Novo Nordisk has unveiled striking Phase 2 trial results for its investigational drug, zenagamtide (also known as amycretin), showcasing significant reductions in HbA1C and an impressive average weight loss of up to 14.6% in adults with type 2 diabetes. Presented at the American Diabetes Association's 2026 Scientific Sessions, these findings position zenagamtide, a first-in-class unimolecular peptide agonist targeting both GLP-1 and amylin receptors, as a formidable contender in the rapidly expanding cardiometabolic therapeutic landscape. The positive data arrive amidst an intensifying battle for market dominance in diabetes and obesity treatments, currently spearheaded by Novo Nordisk semaglutide (Ozempic, Wegovy) and Eli Lilly tirzepatide (Mounjaro, Zepbound). While existing GLP-1 receptor agonists have set high benchmarks, zenagamtide dual-action mechanism, which includes an amylin receptor agonist, hints at potentially superior efficacy in both glycemic control and weight reduction, without an observed plateau in weight loss at higher doses. This is a critical differentiator in a market where rivals are constantly innovating with dual and triple agonists to enhance patient outcomes and capture market share. Bolstered by these compelling Phase 2 outcomes, Novo Nordisk plans to accelerate zenagamtide into Phase 3 clinical trials for type 2 diabetes in the second half of 2026, with separate programs also investigating its use for overweight or obesity. The swift progression underscores the urgency within the pharmaceutical industry to deliver next-generation solutions that not only manage chronic conditions but also address the broader spectrum of cardiometabolic health, promising a new era of more effective treatment options for millions worldwide.